A change in one gene can disrupt thousands of others in HD. A study in pigs suggests an explanation: expanded huntingtin ...

Its speech measures reflected clinical scores and HD-related changes over time, suggesting it could be used as a remote ...

Regular HDBuzz readers may recall our September 2024 article examining the long history of pridopidine in Huntington’s disease (HD) research. In that piece, we covered the drug’s journey through four ...

Huntington’s disease (HD) is typically viewed as a brain disorder, but new research highlights its lesser-known effects on the body, especially on muscles, fat, and nutrition, even in the early stages ...

In plain language. Written by scientists. Scientists discovered that a specific type of brain cell becomes unusually quiet in Huntington’s disease. By restoring the activity of these cells in mice, ...

As promised, HDBuzz's Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD "observational study" here. The Enroll-HD study is the largest clinical study in ...

Results from the VIBRANT-HD trial are now published in a peer reviewed journal. This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the ...

Day 1 of HD2026 is a wrap! From what human brains can teach us about HD, to HTT1a, somatic CAG expansion and the normal biology of HTT, today’s talks spanned the spectrum from fundamental biology to ...

A highly-anticipated scientific paper has landed! This new work challenges current theories in Huntington’s disease research, uncovering how runaway CAG repeats erode cell identity in certain types of ...

After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the ...

Today, Roche announced in a community letter difficult news for the Huntington’s disease (HD) community, discontinuing two separate clinical programmes after new data emerged from ongoing studies. The ...

Skyhawk Therapeuticstherapeutics treatments has announced by press release new 12-month data from their Phase 1/2 trial of SKY-0515, an experimental oral treatment for Huntington’s disease (HD). The ...